For Spain’s billionaire Grifols family, which turned a blood-collection business into one of the world’s largest medical ...

Grifols said it plans to outline its strategy as a standalone company after Brookfield Asset Management dropped out of talks ...

Brookfield Asset Management Ltd. walked away from a plan to acquire Grifols SA, ending months of negotiations to take over ...

Canadian fund Brookfield said on Wednesday it has dropped its plan to take over Spain's Grifols due to a disagreement over ...

Brookfield withdrew its bid for the Spanish pharmaceutical company following a deadlock between the two side over price ...

Brookfield Asset Management Ltd. is preparing to walk away from a plan to acquire Grifols SA over disagreements on valuation.

The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield ...

Grifols (NASDAQ:GRFS) has commenced discussions with banks to refinance its bonds due in 2025, Bloomberg News reported, a day ...

Law firm Araoz y Rueda has been independently engaged by several international and Spanish institutions (the "Clients") holding in aggregate 5.65% of A shares and 3.88% of B shares (including ADRs) in ...

Spain’s billionaire Grifols family said it won’t support a new bid by a third-party to take its namesake drug-maker private, ...

Grifols rejects Brookfield’s €10.5/share offer, signaling undervaluation. Read why GRFS stock is a strong "Buy" despite the ...

In a notice to the Spanish National Securities Market Commission, Grifols (GRFS) stated: “Grifols announces that its Board of Directors held an ...